Dihexa: The Most Potent Synaptogenic Peptide Ever Studied — And Why That's Both Exciting and Complicated

The renin-angiotensin system (RAS) is primarily known for blood pressure regulation. But a lesser-known branch of the RAS — the angiotensin IV (Ang IV) fragment and its AT4 receptor — was found in the early 2000s to play a role in learning and memory. The AT4 receptor (now identified as IRAP, insulin-regulated aminopeptidase) is highly expressed in memory-relevant brain regions including the hippocampus and cortex. ^[6]

The problem with native Ang IV as a drug candidate was its metabolic instability: it was cleaved too rapidly by peptidases to maintain therapeutic concentrations in vivo. The Wright/Harding lab at Washington State University spent years synthesizing and screening metabolically stable analogs. Dihexa (also called PNB-0408) was their lead compound: it bound AT4/IRAP with high affinity, was resistant to enzymatic breakdown, and — crucially — could cross the blood-brain barrier after peripheral administration, including orally. ^[1]

Why the HGF/c-Met angle matters:
The 2013 paper proposed that Dihexa doesn't work directly through AT4/IRAP — rather, it activates the hepatocyte growth factor (HGF) / c-Met receptor signaling pathway, which then drives synaptogenesis. HGF/c-Met is known to regulate neurite outgrowth, synaptic plasticity, and neuronal survival. The proposed mechanism was that Dihexa mimics HGF's pro-synaptogenic signaling — producing new synaptic connections at extraordinarily low concentrations. ^[2]

The 2014 retraction complicates this picture: the paper making the strongest mechanistic case for the HGF/c-Met pathway was formally retracted, weakening (though not eliminating) the proposed molecular mechanism. The earlier 2010 animal cognition data and the 2014 animal study of procognitive effects remain in the literature. ^[4,5]

The Dihexa evidence base consists entirely of preclinical studies — in vitro cell culture and rodent in vivo experiments. There are no published human clinical trials. Here's what the animal data shows, and what it doesn't: ^[1,2,3]

In vitro: Synaptogenesis
In hippocampal cell culture, Dihexa produced synaptogenic effects at concentrations approximately 10 million-fold lower than BDNF in specific assay conditions. This headline figure drove enormous interest in the compound. Caveat: Dihexa has poor aqueous solubility, and researchers have flagged that precipitation artifacts in low-concentration in vitro studies may have inflated apparent potency. The absolute potency number should be interpreted with this uncertainty in mind.

In vivo (rats): Cognition in scopolamine-impaired model
Oral Dihexa reversed scopolamine-induced memory deficits in rats on the Morris Water Maze task. Treated animals performed comparably to unimpaired controls. This model is commonly used to screen Alzheimer's candidates. ^[1]

In vivo (rats): Aged rodent cognition
Aged rats showed improved spatial memory after Dihexa treatment, with histological evidence of increased hippocampal dendritic spine density — consistent with the proposed synaptogenic mechanism. ^[2]

What is NOT in the evidence base:

• No Phase 1 safety study in humans
• No Phase 2 efficacy study in humans
• No pharmacokinetic data in humans (plasma levels, CNS penetration in humans)
• No dose-response data in humans
• No long-term safety data in any species
• No data on cancer risk with chronic use (c-Met pathway activation is theoretically oncogenic in the context of pre-existing cancer)

One of Dihexa's most pharmacologically interesting properties is its ability to cross the blood-brain barrier after oral administration. Most research peptides require injection to achieve CNS activity — the GI tract destroys them before absorption, or the BBB blocks them even if they reach plasma. Dihexa bypasses both obstacles.

This is achieved through two structural modifications relative to native Ang IV:

• N-hexanoyl capping: Adding a hexanoic acid group to the N-terminus makes the peptide more lipophilic, improving membrane permeability and resisting peptidase cleavage from the N-terminus
• C-terminal hexanoic amide: Similarly protects the C-terminus from carboxypeptidase degradation and enhances lipophilicity

These modifications allow Dihexa to survive oral administration, be absorbed through intestinal mucosa, circulate in plasma, and penetrate the BBB — all without the injection that virtually all other research peptides with CNS targets require. In rodent studies, oral and subcutaneous administration produced comparable cognitive effects. ^[1]

For researchers, this means Dihexa can theoretically be administered as a transdermal cream, sublingually, or orally — though dissolution challenges (the same solubility issues that affect in vitro studies) affect the practical reliability of oral dosing.

No validated human dosing protocol exists for Dihexa. All dose estimates in current use are extrapolated from animal data using allometric scaling. The community-reported doses are:

• Common range: 5–10 mg per day (oral or transdermal)
• Higher protocols: Some researchers report 15–20 mg, but no safety justification exists for this range
• Animal studies used: ~1 mg/kg in rodents; allometric scaling to humans suggests approximately 150–175 mcg/kg as a rough equivalent — but interspecies extrapolation for CNS compounds is notoriously unreliable
• Cycle length: Anecdotal protocols typically run 7–14 days, then assess, due to concern about persistent synaptogenic effects

Solubility is a practical challenge. Dihexa has poor water solubility but dissolves in DMSO and propylene glycol — hence the popularity of transdermal formulations. Oral capsules require careful formulation to ensure dissolution before the peptide is degraded.

Given the absence of human pharmacokinetic data, researchers cannot be certain that any given oral dose actually reaches the CNS at an effective concentration — or what that concentration would be in humans.